0001209191-19-002822.txt : 20190108 0001209191-19-002822.hdr.sgml : 20190108 20190108165912 ACCESSION NUMBER: 0001209191-19-002822 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190104 FILED AS OF DATE: 20190108 DATE AS OF CHANGE: 20190108 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hahn Mark W CENTRAL INDEX KEY: 0001408502 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38135 FILM NUMBER: 19516552 MAIL ADDRESS: STREET 1: 6340 QUADRANGLE DRIVE STREET 2: SUITE 100 CITY: CHAPEL HILL STATE: NC ZIP: 27517 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dova Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001685071 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813858961 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 240 LEIGH FARM ROAD CITY: DURHAM STATE: NC ZIP: 27707 BUSINESS PHONE: 919-806-4487 MAIL ADDRESS: STREET 1: 240 LEIGH FARM ROAD CITY: DURHAM STATE: NC ZIP: 27707 FORMER COMPANY: FORMER CONFORMED NAME: Dova Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20160919 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-01-04 0 0001685071 Dova Pharmaceuticals Inc. DOVA 0001408502 Hahn Mark W C/O DOVA PHARMACEUTICALS, INC. 240 LEIGH FARM ROAD, SUITE 245 DURHAM NC 27707 0 1 0 0 Chief Financial Officer Common Stock 2019-01-04 4 A 0 8844 A 11344 D Employee Stock Option (right to buy) 8.82 2019-01-04 4 A 0 250000 0.00 A 2029-01-03 Common Stock 250000 250000 D Represents a restricted stock unit ("RSU") award that vests 50% on each of June 30, 2019 and 25% on each of September 30, 2019 and December 31, 2019. Each RSU represents a contingent right to receive one share of Issuer common stock. 25% of the total shares subject to the option shall vest on December 31, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service with the Issuer as of each such date. The option allows for early exercise, subject to the Issuer's repurchase option, with respect to any unvested shares of Common Stock. /s/ Mark Ballantyne, Attorney-in-Fact 2019-01-08